CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Advances in the critical care management for patients with hematological malignancies.
Advances in the critical care management for patients with hematological malignancies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
血液系统恶性肿瘤(HMs)越来越多地伴发需要重症监护病房(ICU)管理的危及生命的并发症。治疗、诊断和重症监护方案的最新进展改善了这些患者的结局,但重大挑战依然存在。本文探讨了血液学重症监护不断发展的格局,重点阐述该领域特有的并发症、管理策略及未来方向。HMs 患者特别容易发生感染、脓毒症、器官功能障碍以及治疗相关毒性,如细胞因子释放综合征(CRS)、免疫效应细胞相关神经毒性综合征(ICANS)和凝血功能障碍。急性呼吸衰竭、感染性休克和侵袭性真菌感染管理方面的创新有助于提高生存率,但某些高危人群的结局仍不理想。
此外,包括 CAR-T 细胞、双特异性抗体和免疫检查点抑制剂在内的新疗法因其潜在毒性,在 ICU 环境中既带来机遇也带来挑战。新兴趋势强调早期入住 ICU、多学科协作和精准医学对于改善患者照护的重要性。整合生物标志物驱动的策略、先进诊断技术和人工智能,有望优化治疗干预并加强抗菌药物管理。
此外,以患者为中心的方法,包括限时试验和以目标为导向的讨论,旨在平衡积极治疗与生活质量考量。本综述强调,仍需继续开展研究,以解决医疗服务可及性方面的差异、改善长期结局,并制定管理危重症血液病患者的标准化方案。通过推进肿瘤学与重症医学的整合,临床医生能够更好地应对现代疗法的复杂性,并提供符合患者价值观和优先事项的整体化、循证照护。
Hematological malignancies (HMs) are increasingly associated with life-threatening complications requiring intensive care unit (ICU) management. Recent advancements in therapies, diagnostics, and critical care protocols have improved outcomes for these patients, yet significant challenges persist. This manuscript explores the evolving landscape of critical care in hematology, emphasizing the unique complications, management strategies, and future directions in the field.
Patients with HMs are particularly vulnerable to infections, sepsis, organ dysfunction, and treatment-related toxicities such as cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and coagulopathies. Innovations in the management of acute respiratory failure, septic shock, and invasive fungal infections have contributed to better survival rates, yet outcomes remain suboptimal for certain high-risk groups.
Furthermore, new therapies, including CAR-T cells, bispecific antibodies, and immune checkpoint inhibitors, present both opportunities and challenges in the ICU setting due to their potential toxicities. Emerging trends emphasize the importance of early ICU admission, multidisciplinary collaboration, and precision medicine in improving patient care. The integration of biomarker-driven strategies, advanced diagnostics, and artificial intelligence holds promise for optimizing therapeutic interventions and enhancing antimicrobial stewardship.
Additionally, patient-centered approaches, including time-limited trials and goal-oriented discussions, aim to balance aggressive care with quality-of-life considerations. This review underscores the need for continued research to address disparities in access to care, improve long-term outcomes, and develop standardized protocols for managing critically ill hematology patients.
By advancing the integration of oncology and critical care, clinicians can better navigate the complexities of modern therapies and provide holistic, evidence-based care that aligns with patient values and priorities.
MEMBER ACCOUNT
登录成功会直接打开下一页。